Registry of Asthma Patients Initiating DUPIXENT® (RAPID)

First published: 18/10/2021

Last updated: 06/08/2026

Study Ongoing

Administrative details

EU PAS number

EUPAS41963

Study ID

46244

DARWIN EU® study

No

Study countries

- Canada
- Denmark
- France
- Italy
- Japan
- Puerto Rico

Spain

Sweden

United Kingdom

United States

Study description

The primary objective of the study is to characterize the patients who initiate treatment for asthma with DUPIXENT® in a real-world setting to understand the attributes of treated patients in real life. This includes characterization of: • Patient demographics (eg, gender, age, and race) • Patient baseline characteristics (eg, prior medications and procedures, medical history, asthma history, weight, height) The secondary objectives of the study are: • To characterize real-world use patterns of DUPIXENT® for asthma • To assess the long-term effectiveness of DUPIXENT® in asthma patients in a real-world setting • To assess effectiveness on comorbid type 2 inflammatory conditions in asthma patients treated with DUPIXENT® • To collect long-term safety data on study participants in the real-world setting

Study status

Ongoing

Research institutions and networks

Institutions

Regeneron Pharmaceuticals

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Contact details

Study institution contact

Study Director Regeneron

clinicaltrialdisclosureteam@regeneron.com

Study contact

clinicaltrialdisclosureteam@regeneron.com

Primary lead investigator

Study Director Regeneron

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual: 26/09/2019

Study start date

Actual: 02/03/2020

Data analysis start date

Planned: 10/06/2026

Actual: 09/06/2026

Date of final study report

Planned: 09/06/2027

Sources of funding

- Other
- Pharmaceutical company and other private sector

More details on funding

Regeneron Pharmaceuticals, Inc., Sanofi (Collaborator)

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Other study registration identification numbers and links

R668-AS-1885,NCT04287621

Methodological aspects

Study type

Study type list

Study topic:

Disease /health condition

Human medicinal product

Study type:

Non-interventional study

Scope of the study:

Drug utilisation

Effectiveness study (incl. comparative)

Evaluation of patient-reported outcomes

Healthcare resource utilisation

Other

Safety study (incl. comparative)

If ‘other’, further details on the scope of the study

Patient Characterization of population receiving therapy and evaluations of safety and effectiveness

Study design:

A prospective global product registry

Main study objective:

This is a prospective global product registry, designed to collect data regarding the characteristics of patients who initiate DUPIXENT for asthma according to the country-specific prescribing information, real-world use patterns for DUPIXENT and any co-treatments, and long-term data on DUPIXENT’s safety and effectiveness in the real-world setting.

Study Design

Non-interventional study design

Cohort

Other

Non-interventional study design, other

Observational prospective product registry

Study drug and medical condition

Medicinal product name

DUPIXENT

Study drug International non-proprietary name (INN) or common name

DUPILUMAB

Anatomical Therapeutic Chemical (ATC) code

(D11AH05) dupilumab

dupilumab

Medical condition to be studied

Asthma

Population studied

Short description of the study population

Patients who initiate DUPIXENT for asthma according to the country-specific prescribing information

Age groups

- Adolescents (12 to < 18 years)
- Adults (18 to < 46 years)
- Adults (46 to < 65 years)
- Adults (65 to < 75 years)
- Adults (75 to < 85 years)
- Adults (85 years and over)

Estimated number of subjects

719

Study design details

Outcomes

• Demography • Baseline Characteristics, • Baseline Treatment Characteristics • Incidence of AEs • Physician Assessments: Spirometry & FeNO • Patient Reported Outcomes (PRO): ACQ-6, MiniAQLQ, Global Patient Assessments, PALQ, & WPAI-asthma • PRO (allergic rhinitis): AR-VAS, RQLQS+12 • PRO (chronic (rhino) sinusitis +/- nasal polyps): SNOT-22 • PRO (AD): POEM • Healthcare Utilization: HCRUQ See ClinicalTrials.gov NCT04287621

Data analysis plan

Data collected in this registry will be analyzed descriptively.

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data sources (types)

Other

Data sources (types), other

Prospective patient-based data collection

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No